The artificial induction of tolerance in transplantation is gaining strength. In mice, a differential role of extracellular adenosine (eADO) for regulatory and effector T cells 17 liver transplant patients were enrolled in an immunosuppression withdrawal trial, and the differences in the CD39-CD73-A 2 R axis were compared between tolerant and nontolerant patients. In contrast to the mice, the activation of human Tregs was inhibited similarly to Teffs in the presence of eADO. Moreover, the expression of the enzyme responsible for the degradation of ADO, adenosine deaminase, was higher in tolerant patients with respect to the nontolerant group along the immunosuppression withdrawal. Our data support the idea that eADO signaling and its degradation may play a role in the complex system of regulation of liver transplant tolerance.
| INTRODUC TI ON
The achievement of immune tolerance to an allogenic graft has been a field of intense research during the past decade, fueled by a critical need to avoid immunosuppression (IS)-related side effects.
Regulatory T cells (Tregs) have been implicated in this process. 2 Interestingly, Tregs can also use the metabolism of extracellular adenosine triphosphate (ATP) to perform IS. 3 ATP is released into the extracellular milieu under inflammatory responses, hypoxia, or other types of cell injury, such as occurs in organ transplant. Extracellular ATP is sensed by the ionotropic purinergic receptor P2X7 (P2X7R) on innate and adaptive immune cells, 4 and it has been associated with allograft rejection. [5] [6] [7] However, inflammation promoted by extracellular nucleotides is subject to regulation by some members of the ectonucleoside family, such as ectonucleotidase triphosphate diphosphohydrolase 1 (CD39) and ecto-5′-nucleotidase (CD73). (LAG-3) mRNA in T cells, suggesting newly induced Tregs (iTregs). 13 Similarly, there has been discussion on how ADO exerts its differential function over T cells; although cyclic AMP (cAMP) and low IL-2 levels are key, 16 the precise mechanism remains unsolved. Sitkovsky 
| MATERIAL S AND ME THODS

| Isolation and purification of T cells
Blood from healthy volunteers was collected on informed consent for T cell purification and in vitro studies. Total T cells were purified from peripheral blood mononuclear cells (PBMCs) by using the Human CD3 
| Culture conditions
| Proliferation assays
Responder 
| Treg suppressive assay
Isolated responder Tconvs (RCs) were autologous to isolated suppressor Tregs (S). RCs were stained with CFSE, whereas S were cultured for 24 hours in the presence or absence of 30 μmol/L ADO.
Subsequently, S were extensively washed and added to RCs at R:S ratios of 1:0.5 and 1:1 in a complete medium containing IL-2 (150 IU/ mL) and ImmunoCult Human CD3/CD28 T Cell Activator in 96-well plates and then cocultured for 4 days. After harvest, the suppression of CFSE-labeled RC proliferation was analyzed by FC. and renal dysfunction (18%) ( Table 1 and Table S1 ). 
| Patients
| Flow cytometry
| Statistical analysis
| RE SULTS
| Extracellular nucleotides inhibit human CD4 + T cell proliferation after its degradation to ADO
First, we examined the effect of extracellular nucleotides in the in vitro proliferation of human T cells after classic activation with anti-CD3 and anti-CD28 in the absence of added IL-2. To this end, we followed the proliferation of CFSE-stained CD4 + T cells by FC ( Figure S1A ). As shown in Figure 1A , all added nucleotides (ATP, ADP, and AMP), and even the nucleoside ADO, inhibited the CD4 + T cell proliferation, as well as IFNγ and IL-2 production ( Figure S1B ). These results were also obtained in the presence of CHET-AMP ( Figure 1A and Figure S1B ), an inactive A 2A R agonist, which requires CD73 dephosphorylation to its active form, CHET- Figure S1C ), and which is able to avoid classic A 2 R agonist side effects, such as hypotension. 22 The activation of P2X7R by extracellular ATP was discarded, as the use of its specific antagonist A438079 had no effect on T cell proliferation inhibition ( Figure 1B ).
However, the inhibition of the degradation of ATP and ADP by blocking the activity of CD39 by ARL67156 or the dephosphorylation of AMP or CHET-AMP inhibiting CD73 with APCP completely reverted the inhibition of T cell proliferation exerted by these nucleotides, suggesting that ADO is responsible for this inhibition ( Figure 1B ). The addition of recombinant human IL-2 to the culture had no effect on the ADO-dependent inhibition of proliferation ( Figure 1C ). Likewise, the CD25 expression in CD4 + T cells after of activation was downregulated in the presence of ADO ( Figure 1D ).
| ADO inhibits the proliferation of Tregs, similar to Teffs
We further analyzed the evolution of Tregs gating for CD4 + FOXP3 high cells on the in vitro activated T cells 23 ( Figure S2A ). We observed the same profile of inhibition of the proliferation as for total CD4 + T cells (Figure 2A ), although the IC 50 for ADO was slightly higher but not statistically significant, for Tregs (11.50 µmol/L) than for Teffs 
| ADO inhibition of human T cell activation is reversible but does not affect natural Treg suppressor capacity
We examined whether eADO signaling would affect the release of principal cytokines involved in Tregs function. As shown in Figure 5A , IL-10, IL-17A, and TGF-β secretion was decreased in the presence of However, when we removed eADO from the culture, T cells recovered its proliferation capacity ( Figure 5C ), and IFNγ and TGF-β production, besides a low release of IL-17A ( Figure 5D ). Moreover, expression of ICER induced by ADO decreased after eADO removal, whereas ADA expression slightly increased when eADO was withdrawn ( Figure 5D ). Likewise, when eADO was removed, we found a higher frequency of FOXP3 high Tregs with a higher FOXP3 expression ( Figure 5E ) compared with those cultures in the absence of eADO ( Figure 5E ).
On the other hand, when we studied the suppressor ability of natural Treg (nTreg), we observed that eADO had no effect, such as 24-hour eADO-stimulated nTregs were able to inhibit the proliferation of isogeneic Tconv cells at the same level as control nTregs ( Figure 5F ). Table 1 respectively; ***P < .0001) ( Figure 6B ). When the plasma concentrations of ATP or ADO were analyzed, ATP was slightly higher in non-Tol patients from the beginning of IS withdrawal until rejection, compared with the Tol group ( Figure 6C ). However, the plasma ADO concentration was higher in the Tol group with respect to the non-Tol group, reaching a significant difference in the R/pre-Tol sample ( Figure 6C ).
Both parameters presented a slight but significant negative correlation (r = −0.364; **P = .004) ( Figure S5A ). Similarly, we found signifi- to other work. 26 As expected, the inhibition of T cell proliferation F I G U R E 6 Adenosine (ADO) signaling in tolerant liver transplant patients. A, B, Plasma levels of cyclosporin A or tacrolimus (A) and the principal liver enzymes AST or ALT (B) in the IS withdrawal follow-up for the 17 studied patients. C, Plasma levels of ADO and ATP expressed in nanomolar concentrations as determined by UPLC-MS-UV or bioluminescence, respectively. D, The percentage of regulatory T cells (Tregs) (CD4 + CD25 high CD127
| D ISCUSS I ON
low/-) that express CD39 or CD73 as determined by flow cytometry from peripheral blood mononuclear cells (PBMCs) and plasma levels of sCD73 as measured by ELISA (Deltaclon). E, F, Relative expression of A 2A R, A 2B R, ADA, and ICER as determined by qPCR from stabilized whole blood. A significant P value in the evolution of ADA and A 2B R relative expression as calculated by Friedman test is represented in blue for the Tol group and red for the non-Tol patients. Significant differences among groups at each time-point were calculated by using 2-way ANOVA for matched values with Bonferroni posttest. Mean (solid line) and 25%-75% percentile (dotted lines) from 12 healthy volunteers was plotted for each variable. a represents statistically significant differences between the Tol and non-Tol group, while b represents statistically significant differences compared with the healthy group. *P ≤ .05; **P ≤ .01; ***P ≤ .001 was mediated by ADO after extracellular nucleotide degradation by However, if ICER is induced, it competes with CREB for DNA binding and may lead to uncoupling of a CBP-mediated TGF-β transcriptional response. 18 Nevertheless, after eliminating the eADO, and so the induction of ICER, these cells are able to hugely express FOXP3.
The modulation of the axis CD39-CD73-A 2 R is a hot topic in the field of transplant and tolerance. 27 However, we found no or slight dif- Strikingly, only ADA mRNA expression presented significant differences in the evolution along the IS withdrawal in Tol patients, whereas its expression remained unaltered in the non-Tol group. Moreover, the differences began to be noticeable before the rejection episode and were significantly different with respect to healthy samples, which confers to ADA expression a great value as a new tolerance biomarker. ADA is ubiquitously expressed and functions as part of the purine salvage pathway.
In certain cell types, it is also complexed with CD26 on the cell surface.
ADA catalyzes the deamination of adenosine, forming inosine. ADA deficiency evokes an accumulation of ADO, which may mediate a defective TCR activation in vivo, leading to severe combined immunodeficiency (SCID). 32 At similar levels of IS, non-Tol patients are not able to induce the expression of ADA, which would entail a lower degradation of ADO, enabling its accumulation ( Figure 7 ). However, we did not see the accumulation of plasmatic ADO in non-Tol patients. Nevertheless, the levels of plasma ADO were in the nanomolar range ( Figure 6C ), similar to those previously published, 33 whereas IC 50 for eADO in the in vitro experiments was about 10 μmol/L. This difference could be due to the extracellular nucleotide concentration reached in the proximity of the plasma membrane surface, where they bind their receptors, which can be up to 20-fold higher than those measured in the bulk medium. 34, 35 Curiously, Tregs from ADA-deficient patients with SCID were reduced in number and showed decreased suppressive activity, which were corrected after gene therapy. 36 In Tol patients, overexpression of ADA would favor the activation of Tregs (Figure 7 ). It could also be related to the decrease of ICER after eADO degradation, allowing the induction of new Tregs coming from non-Tregs 18 ( Figure 7 ). Although exist a complete correlation between ADA and ICER evolution does not in the prospective study, it is worth noting that patient samples were extracted from complete blood, whereas in vitro experiments were carried out in isolated T cells. Further studies to determine the exact cells that modulate this expression after IS withdrawal will be necessary. Moreover, these findings are consistent with the idea that tolerance needs an active and well-functioning immune system during the process. 37 In theory, the ability of A 2A R agonists to promote T cell tolerance in mice suggests that such agents could be used in transplant, promoting long-term, peripheral tolerance in the absence of continued IS. 13 However, paradoxically, considering the present data, the use of these agonists in human transplant suggest they could be harmful because they mimic a rejection scenario ( Figure 7) . Nevertheless, the use of A 2 R antagonists could be considered as beneficial in the search for a state of operational tolerance ( Figure 7) . 
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